COVID-19: HHS-NIH-NIAID-BAA2020-1: Research Area 004, Development of Therapeutics Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2020-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Biocryst Pharmaceuticals Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020C00055 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
This cost-reimbursement contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to BIOCRYST PHARMACEUTICALS, INC. on August 31, 2020 is for $43,907,603.00 to manufacture and evaluate the safety, efficacy and tolerability of galidesivir, a broad spectrum antiviral therapeutic, in an effort to develop treatments for biodefense, antimicrobial resistant infections and emerging infectious diseases such as COVID-19.
Notice text
COVID-19: This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. This contract is to manufacture and evaluate the safety, efficacy and tolerability of galidesivir a broad spectrum, antiviral therapeutic.
Awarded contract 75N93020C00055 to BIOCRYST PHARMACEUTICALS, INC. for 43907603.00 on 2020-08-31.
Notice history
| Notice | Type | Posted |
|---|---|---|
| 2020 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2020 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2020 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| This notice | Award Notice | |
| 2020 NIAID Omnibus Broad Agency Announcement | Solicitation | |
| 2020 NIAID Omnibus Broad Agency Announcement | Pre-Solicitation |
6 of 11 notices listed here. See the rest on GovTribe.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity